Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Revvity ( (RVTY) ) just unveiled an announcement.
Revvity announced it will release its fourth quarter and full-year 2024 financial results on January 31, 2025, followed by a conference call led by CEO Prahlad Singh and CFO Max Krakowiak. The company expects fourth-quarter revenue growth of approximately 5% to 6% and anticipates meeting or exceeding its full-year 2024 adjusted earnings per share guidance. Revvity is also set to present at the J.P. Morgan Healthcare Conference, where it will discuss these financial results and future projections, reflecting its strong positioning in the healthcare industry.
More about Revvity
Revvity, Inc. is a healthcare company providing health science solutions, technologies, expertise, and services that cover workflows from discovery to cure. With a focus on translational multi-omics technologies, biomarker identification, imaging, detection, diagnosis, and informatics, Revvity serves pharmaceutical, biotech, diagnostic labs, academia, and governments globally, generating over $2.7 billion in revenue in 2023 with more than 11,000 employees.
YTD Price Performance: 1.68%
Average Trading Volume: 885,010
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.86B
Learn more about RVTY stock on TipRanks’ Stock Analysis page.
